# Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea (OSA/H) Syndrome

> **NCT00079677** · PHASE3 · COMPLETED · sponsor: **Cephalon** · enrollment: 263 (actual)

## Conditions studied

- Obstructive Sleep Apnea
- Sleep Hypopnea

## Interventions

- **DRUG:** Armodafinil 150 mg/day
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00079677
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2004-10
- **Target enrollment:** 263 (ACTUAL)
- **Last updated:** 2013-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00079677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00079677, "Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea (OSA/H) Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00079677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*